Stronger Together: Uniting Minds, Achieving Science
Empowering health resilience across communities, we strive to set a new standard in wound care. Fueled by our commitment to innovation and dedication to protecting lives, we aim to redefine the boundaries of healthcare, ensuring our technology becomes the benchmark for safety, treatment, and healing worldwide
TEGSAL: Driving Innovation in Medical Technology
Tegsal was founded in July 2023 with the goal of harnessing the commercial potential of groundbreaking technology originating from the University of Colorado Denver, Anschutz Medical Campus. Our company is built upon the diverse expertise and dedication of key team members who bring a wealth of knowledge and experience to drive our mission forward.
Our endeavor has received support from the Colorado Office of Economic Development and International Trade (COEDIT) through the SPARK|REACH grant program. We were participants in the 2023 National NSF I-CORPs program, and have done extensive product market fit validation and customer discovery activities.
Tegsal has also established strategic partnerships and affiliations, including participation in the Innosphere Life-Sciences Incubator Program and collaboration with CU Innovations, the CU AMC Technology Transfer Office. These partnerships have cultivated a robust network of subject matter experts, mentors, and advisors, all of whom contribute significantly to the success of our commercial venture.
Dr. Daewon Park, PhD. Founder & CTO
Meet Dr. Daewon Park, Ph.D., an accomplished Associate Professor in the Department of Bioengineering at the University of Colorado Denver Anschutz Medical Campus. With a distinguished career spanning research in biomaterials, therapeutic delivery systems, and tissue engineering, Dr. Park is also the visionary Founder & CTO of Tegsal. His groundbreaking work has secured significant research funding, led to innovative studies on Alzheimer's disease and cardiac regeneration, and resulted in numerous patents. Dr. Park's collaborative spirit extends to diverse medical fields, while his commitment to education and mentorship has shaped the next generation of scientists. Beyond the lab, he enjoys mountain biking, hi-fi audio systems, and quality family time. Connect with Dr. Park and explore his impactful contributions at LinkedIn and reach out directly at parktbrl.com.
Lucas Duncan, CEO
Lucas Duncan, Msc, MBA, serves as the CEO and boasts a comprehensive educational background, including a Bachelor's degree in Integrative Physiology from CU Boulder, a Master of Science in Bioengineering, and an MBA from CU Denver, accompanied by a Certificate of Bioinnovation and Entrepreneurship. His career has been dedicated to medical device entrepreneurship and biomaterials, with roles such as Quality Engineer at Medtronic, Quality Engineer II at Livanova, and Senior Sterilization and Manufacturing Engineer at Boulder iQ. Notably, Lucas holds a patent pending for the innovative Tegsal technology. He has contributed to the field by instructing and assisting in biomedical engineering courses. Beyond work, Lucas enjoys spending quality time with his daughter and family, indulging in cooking, golfing, and passionately supporting Colorado's sports teams. To connect with him, please visit his LinkedIn profile at LinkedIn Profile.
Our founding team comprises Dr. Daewon Park, an Associate Professor in the Department of Bioengineering at CU Denver, and Lucas Duncan, a PhD student in the same department. Dr. Park boasts decades of experience in the development of translational biomaterials across a wide spectrum of disease states. On the other hand, Lucas holds both an MBA and a Masters of Science in Bioengineering, complemented by over 7 years of multifaceted experience within the medical device industry.
As part of our journey to realize the commercial potential of our technology, we have actively engaged with industry mentor Barry Marston through our participation in regional and national I-Corps programs. Barry continues to collaborate with our project group, providing valuable insights as a commercialization and marketing advisor.
Furthermore, our endeavor has received support from the Colorado Office of Economic Development and International Trade through the SPARK|REACH grant program. This grant is specifically designed to advance the technology to a technology transfer event, setting the stage for licensing from the University before embarking on Phase I activities, thereby further mitigating risks on the commercialization pathway.
Tegsal has also established strategic partnerships and affiliations, including participation in the Innosphere Life-Sciences Incubator Program and collaboration with CU Innovations, the CU AMC Technology Transfer Office. These partnerships have cultivated a robust network of subject matter experts, mentors, and advisors, all of whom contribute significantly to the success of our commercial venture.